A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants
Condition: Healthy Volunteers Interventions: Drug: Acalabrutinib; Drug: Fluconazole; Drug: Isavuconazole Sponsor: Acerta Pharma BV Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 1, 2021 Category: Research Source Type: clinical trials
